Page last updated: 2024-12-07

aristolochic acid ii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Aristolochic acid II is a naturally occurring nitrophenanthrene compound found in plants of the Aristolochia genus. It is a potent nephrotoxin and carcinogen, and has been implicated in the development of Balkan endemic nephropathy. Aristolochic acid II is of significant interest to researchers due to its carcinogenic properties and its potential role in the development of human diseases. It is being studied to understand its mechanism of action, to identify biomarkers for exposure, and to develop strategies for prevention and treatment of aristolochic acid II-induced diseases.'

aristolochic acid II: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aristolochic acid B : An aristolochic acid that is phenanthrene-1-carboxylic acid substituted by a methylenedioxy group at the 3,4 positions and by a nitro group at position 10. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID108168
CHEMBL ID602280
CHEBI ID194149
SCHEMBL ID571697
MeSH IDM0125018

Synonyms (39)

Synonym
brn 0329754
aristolochic acid ii
6-nitrophenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid
phenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid, 6-nitro-
einecs 207-499-6
aristolochic acid b
ccris 6497
CHEMBL602280 ,
bdbm50306854
6-nitro-2h-phenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
CHEBI:194149
6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
475-80-9
unii-bb72d5pu2y
bb72d5pu2y ,
5-19-07-00425 (beilstein handbook reference)
3,4-(methylenedioxy)-10-nitrophenanthrene-1-carboxylic acid
FT-0622473
AKOS015889601
SCHEMBL571697
AC-34517
Q-100503
6-nitrophenanthro(3,4-d)-3-dioxole-5-carboxylic acid
DTXSID00197166 ,
aristolochic acid b, >=97% (hplc)
6-nitro-phenanthro-[3,4-d]-1,3-dioxole-5-carboxylic acid
mfcd01708574
aristolochic acid ii , hplc grade
Q2548975
CS-0009051
HY-N0511
10-nitro-3,4-(epoxymethanoxy)phenanthrene-1-carboxylic acid
A904448
B2703-350870
AS-78438
6-nitronaphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid
GOR ,
aristolochicacidb
dtxcid10119657

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The isolated toxic compounds were purified through RP-HPLC."( Toxicity of aristolochic acids isolated from Aristolochia indica Linn (Aristolochiaceae) against the malarial vector Anopheles stephensi Liston (Diptera: Culicidae).
Kirubakaran, SA; Pradeepa, V; Sathish-Narayanan, S; Senthil-Nathan, S; Thanigaivel, A, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" After a single intravenous dose of 5 mg kg(-1) AA in rats, the pharmacokinetic parameters were estimated."( [Study of pharmacokinetics of aristolochic acid I and II in rats].
Chen, XJ; Fang, F; Lu, Q; Wang, GJ, 2008
)
0.35
" The main pharmacokinetic parameters were estimated to be as follows: CL = (0."( [Study of pharmacokinetics of aristolochic acid I and II in rats].
Chen, XJ; Fang, F; Lu, Q; Wang, GJ, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
nephrotoxinA poison that interferes with the function of the kidneys.
toxinPoisonous substance produced by a biological organism such as a microbe, animal or plant.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
aristolochic acidsOrganic heterotetracyclic compounds which are a group of nitro phenanthrene organic acids, naturally found in many kinds of plants, such as Aristolochia and Asarum, and widely cultivated in Asia.They are identified as a class 1 human carcinogen by the International Agency for Research on Cancer owing to their carcinogenicity and nephrotoxicity and can pose a significant hazard to food safety and human health.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
cyclic acetalAn acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
monocarboxylic acidAn oxoacid containing a single carboxy group.
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)20.00000.00041.044410.0000AID457604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID457604Inhibition of CDK22010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
AID457612Inhibition of CDK2 at 50 uM2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (14.58)18.7374
1990's3 (6.25)18.2507
2000's17 (35.42)29.6817
2010's20 (41.67)24.3611
2020's1 (2.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (98.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]